All In Biotech

Drug Trial Radar · NCT06907043

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Eikon TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Impact Therapeutics, Inc.
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

Conditions

  • Advanced Solid Tumors

Interventions

  • EIK1004-001 (IMP1707-001)Drug

    PARP1 selective inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who experience a Dose-Limiting Toxicity (DLT)Time frame: (Timeframe: up to 28 days)
  2. Number of participants with adverse events, treatment emergent adverse events or serious adverse eventsTime frame: (Time Frame: 1 month post last dose of EIK1004 (IMP1707)

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthOne

    Denver, Colorado · Recruiting

  • Florida Cancer Center

    Lake Mary, Florida · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • PASO Medical

    Frankston, Victoria, Australia · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.